novo nordisk semaglutide mash Wegovy® (semaglutide injection) Receives Conditional Marketing Authorization from Health Canada as the First and Only Treatment for Adults with Non-Cirrhotic MASH, a Serious Liver Disease Novo Nordisk seeks approval for

We found significant structural disorganization in H&E-stained hippocampal samples from the HFD SAL group compared to those from the HFD SEMA group

- 2 mg (2000 mcg)**: This maintenance dose ramps up the effects, offering enhanced appetite control and weight loss benefits

Conversely, in patients receiving tirzepatide 10 mg, both escalation to 15 mg and switching to semaglutide 7.2 mg were associated with further weight reduction

Tirzepatide bloating often peaks in the first few weeks and responds well to dietary adjustments

Aptamer-based proteomic analyses of serum samples from patients with MASH in a clinical trial identified 72 proteins significantly associated with MASH resolution and semaglutide treatment, with most related to metabolism and several implicated in fibrosis and inflammation